Cellular Immunity, Peripheral Blood Lymphocyte Count and Pathological Staging of Tumours in the Gastrointestinal Tract

Bone, G; Lauder, I.

doi:10.1038/bjc.1974.184

Cited by 40 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 In addition, a linear inverse association between the stage of colon cancer (Dukes B, C, or D lesions) and lymphocyte counts has been reported. 3 The present study tested the basic question of whether the pretreatment lymphocyte count was related to survival in patients with advanced colon cancer. No association between lymphocyte count and either response to chemotherapy or survival was seen in these patients.…”

Section: Discussionmentioning

confidence: 99%

Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil. Prognostic aspects of the differential white blood cell count

Chlebowski

Silverberg

Pajak

et al. 1980

Cancer

View full text Add to dashboard Cite

One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs. cytoxan, 15 mg/kg/week IV, on day 1 and 5-FU, 15 mg/kg/week IV during weeks 2--5, repeated in a six-week cycle. Age, sex, performance status, and disease free intervals, were comparable in both arms. Response frequency was 11% for treatment with 5-FU alone and 10% for treatment with combination therapy. The median survival time was significantly greater in the 5-FU-alone arm (8.4 months vs. 5.6 months, P less than 0.05). In both arms, survival was correlated with the nadir white blood count (WBC) achieved during therapy (P less than 0.02). Fourteen patients had pretreatment WBC of greater than 12,000/mm3. None of them had fever, bone marrow involvement with tumor, or recognizable infection at study entry. The 14 patients had a median survival time of 2.3 months, significantly shorter than that of patients with normal pretreatment WBC (P less than 0.05). A pretreatment lymphocyte count was available for all patients. No association between this value and either response to chemotherapy or survival time was noted. These results support the superiority of 5-FU to the combination of 5-FU and cytoxan in the treatment of colon carcinoma, and point to the prognostic significance of the pretreatment WBC in this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil. Prognostic aspects of the differential white blood cell count

Chlebowski

Silverberg

Pajak

et al. 1980

Cancer

View full text Add to dashboard Cite

show abstract

“…One explanation of this, that tumour growth and spread lead to specific immunological paralysis, agrees with our findings that colon carcinoma antigens inhibit the cytotoxic lymphocytes.6-8 A similar inverse relation between tumour spread and both skin immunoreactivity to dinitrochlorobenzene and blood lymphocyte count has been reported. 9 Our finding that well-differentiated tumours are associated with antitumour lymphocyte cytotoxicity, more than those of poorer differentiation, may be a function of the greater spread by the latter. Alternatively or in addition, poorly differentiated tumours readily metastasizing might be weakly antigenic and not stimulate the host's immune response.…”

Section: Discussionmentioning

confidence: 80%

Colonic carcinoma: clinicopathological correlation with immunoreactivity.

Pihl¹,

Hughes²,

Nind³

et al. 1975

BMJ

View full text Add to dashboard Cite

show abstract

“…I ) . Paticnts without axillary metastasis (group I) had a 5-year disease-free probability of 78 f 7%, patients with 1-3 positive axillary nodes or those with primary less than 5 cm and 3 4 positive nodes (group 11) had a 5-year disease-free probability of 56*9%, and those with primary cancer greater than 5 cm and 2 4 positive axillary lymph nodes (group 111) had a relapsefree rate of 25*9% (x' = 26.9.9, DF =2, P < 5 x…”

Section: Resultsmentioning

confidence: 99%

Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests in patients with breast carcinoma

Lee

1984

Journal of Surgical Oncology

View full text Add to dashboard Cite

General immunocompetence was examined in 125 patients with various stages of breast cancer. Tests include peripheral blood lymphocyte count, serum protein electrophoresis, quantitative immunoglobulins, CEA level, and delayed cutaneous hypersensitivity (DCH) reaction to six recall antigens (PPD, Monilia, mumps, Varidase, histoplasmin, and coccidioidin). About one third of the patients responded positively to each of the first four antigens, whereas 12% reacted to histoplasmin and 4% to coccidioidin. In this study, DCH to recall antigens had no prognostic value because the distributions of skin test reactivity were similar among patients with different stages of breast carcinoma. And among patients with similar stage of disease the relapse rates were similar for those who reacted and those who were anergic. But peripheral lymphocyte count had definite prognostic value because patients with advanced stage (group III/IV) and those who were anergic had significantly lower lymphocyte counts. Among patients with relatively early stages of breast carcinoma (group I/II), those who had higher lymphocyte count (greater than or equal to 2,000/mm3) had lower chance of having relapse up to 5 years after mastectomy.

show abstract

Cellular Immunity, Peripheral Blood Lymphocyte Count and Pathological Staging of Tumours in the Gastrointestinal Tract

Cited by 40 publications

References 21 publications

Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil. Prognostic aspects of the differential white blood cell count

Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil. Prognostic aspects of the differential white blood cell count

Colonic carcinoma: clinicopathological correlation with immunoreactivity.

Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests in patients with breast carcinoma

Contact Info

Product

Resources

About